TCTR20220210004Enrolling By Invitation2 期
A Study of Therapeutic Equivalence of mometasone cream and Elomet cream in eczema
Zuellig Pharma0 个研究点目标入组 80 人开始时间: 2022年2月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •1. Age 18-60 years old
- •2. Diagnosis of eczema for example irritant contact dermatitis, allergic contact dermatitis, atopic dermatitis, seborrheic dermatitis and nummular eczema
- •3. New lesion of eczema or recurrent eczema that stop topical treatments for 2 weeks or stop systemic treatments for 4 weeks
- •4. Can follow up at day 0, 7, 14, 21 and 28
排除标准
- •1. Use topical treatments within 2 weeks
- •2. Use systemic treatments or immunosuppressive drugs within 4 weeks
- •3. Have others skin infections
- •4. Pregnancy or breast feeding
- •5. Allergy to steroid or other components in cream that we use in the research
研究者
相似试验
Enrolling By Invitation
2 期
A study of therapeutic equivalence of mometasone lotion and Elomet lotion in seborrheic dermatitis of scalpSeborrheic dermatitis of scalpSeborrheic dermatitis of scalp, mometasone lotion, Elomet lotionTCTR20220215001HOE Pharmaceuticals Sdn. Bhd.100
进行中（未招募）
不适用
The effectiveness of Mometasone Furoate plus Isotonic Nasal Saline in the Elderly with RhinitisJ31.0Chronic rhinitisRBR-498bnqPrograma de Pós Graduação em Ciências Médicas da Universidade Federal Fluminense
尚未招募
2 期
se of various topical ointments for the treatment of localized hair lossCTRI/2022/04/041728SOA University
招募中
3 期
The effect of topical Mometasone 0.1% and topical Hydrocortisone 1% in the prevention of acute radiation dermatitis of breastIRCT20180222038825N1Esfahan University of Medical Sciences120
已完成
不适用
STUDY ON THE EFFICACY AND SAFETY OF MOMETHASONE FUROATE IN DRY POWDER INHALER IN THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE-J449 Chronic obstructive pulmonary disease, unspecifiedChronic obstructive pulmonary disease, unspecifiedJ449PER-029-01SCHERING PLOUGH RESEARCH INSTITUTE,